Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Ofatumumab for rituximab-resistant nephrotic syndrome.

× No keyword cloud information.

47 in total

1. Ofatumumab for the treatment of childhood nephrotic syndrome.

Authors: Chia-Shi Wang; Rochelle Schmidt Liverman; Rouba Garro; Roshan Punnoose George; Anastacia Glumova; Alana Karp; Stephanie Jernigan; Barry Warshaw
Journal: Pediatr Nephrol Date: 2017-02-17 Impact factor: 3.714

Review 2. Immunology of idiopathic nephrotic syndrome.

Authors: Manuela Colucci; Giorgia Corpetti; Francesco Emma; Marina Vivarelli
Journal: Pediatr Nephrol Date: 2017-04-27 Impact factor: 3.714

Review 3. Treatment of membranous nephropathy: time for a paradigm shift.

Authors: Piero Ruggenenti; Fernando C Fervenza; Giuseppe Remuzzi
Journal: Nat Rev Nephrol Date: 2017-07-03 Impact factor: 28.314

4. Ofatumumab-associated acute respiratory manifestations: clinical characteristics and treatment.

Authors: Alice Bonanni; Enrica Bertelli; Andrea Moscatelli; Elisabetta Lampugnani; Monica Bodria; Pietro Ravani; Gian Marco Ghiggeri
Journal: Br J Clin Pharmacol Date: 2016-06-28 Impact factor: 4.335

Review 5. B Cell-Based Treatments in SLE: Past Experience and Current Directions.

Authors: Stamatis-Nick C Liossis; Chrysanthi Staveri
Journal: Curr Rheumatol Rep Date: 2017-11-04 Impact factor: 4.592

6. Adverse events linked with the use of chimeric and humanized anti-CD20 antibodies in children with idiopathic nephrotic syndrome.

Authors: Alice Bonanni; Marta Calatroni; Matteo D'Alessandro; Sara Signa; Enrica Bertelli; Michela Cioni; Eddi Di Marco; Roberto Biassoni; Gianluca Caridi; Giulia Ingrasciotta; Roberta Bertelli; Armando Di Donato; Maurizio Bruschi; Alberto Canepa; Giorgio Piaggio; Pietro Ravani; Gian Marco Ghiggeri
Journal: Br J Clin Pharmacol Date: 2018-03-25 Impact factor: 4.335

Review 10. Minimal Change Disease.

Authors: Marina Vivarelli; Laura Massella; Barbara Ruggiero; Francesco Emma
Journal: Clin J Am Soc Nephrol Date: 2016-12-09 Impact factor: 8.237

Ofatumumab for rituximab-resistant nephrotic syndrome.